Prof. Dr. Esma Güldal Altunoğlu

Spécialité

• Médecine interne
• Check-up et bilan de santé général

Établissement

• Medical Park Göztepe Hospital

Formation et spécialisation

• 1973–1979 Faculté de médecine de l’Université Hacettepe
• 1981–1985 Hôpital de formation et de recherche Haydarpaşa

Expérience

• Hôpital Medical Park Göztepe
• 2002–2022 Hôpital de formation et de recherche d’Istanbul
• 1993–2001 Hôpital de formation et de recherche SSK Okmeydanı
• 1992–1993 Hôpital de formation et de recherche SSK Göztepe
• 1985–1991 Hôpital SSK de Çayeli
• 1981–1985 Hôpital de formation et de recherche Haydarpaşa Numune
• 1979–1981 Centre de santé de Bilecik Bozüyük

Titres universitaires

• 2021 Professeure de médecine interne
• 2015 Professeure associée de médecine interne

Affiliations professionnelles

• Société turque de médecine interne
• Association turque du diabète
• Association de l’obésité
• Groupe du diabète de Marmara
• Présidence du premier groupe régional du diabète d’Istanbul
• Membre du conseil scientifique des cliniques de médecine interne d’Istanbul

Publications scientifiques

• E. Altunoğlu et al. "The Impact of Obesity and Insulin Resistance on Iron and Red Blood Cell Parameters: A Single Center, Cross-Sectional Study." Turkish Journal of Hematology, 31, 61–67, March 2014. DOI:10.4274/Tjh.2012.0187.
• G.G. Korkmaz et al. "The Association of Oxidative Stress Markers with Conventional Risk Factors in the Metabolic Syndrome." Metabolism, 62, 828–835, January 2013. DOI:http://dx.doi.org/j.metabol.2013.01.002.
• A. Acay et al. "Evaluation of Serum Paraoxonase and Arylesterase Activities in Subjects with Asthma and Chronic Obstructive Lung Disease." Clinical Laboratory, 59, 1–7, October 2013. DOI:10.7754/Clin.Lab.2013.121144.
• M.S. Gönen et al. "The Risk of Severe Hypoglycemia in Patients with Type 2 Diabetes Mellitus Starting Insulin Therapy with Premixed Insulin Analogues Taken Twice Daily." Turkish Journal of Endocrinology and Metabolism, 17, 83–88, March 2014. DOI:10.4274/Tjem.2134.
• A.S. Demir et al. "Diagnostic and Prognostic Value of Tumor M2-Pyruvate Kinase Levels in Patients with Colorectal Cancer." Turkish Journal of Gastroenterology, 24, 36–42, March 2013. DOI:10.4318/tjg.2013.0607.
• F. Erdenen et al. "Thyroid Disease, TSH Screening, and Comorbidity." Nobel Medicus, 7, 88–93, January 2011.
• F. Erdenen et al. "Evaluation of Disability, Anxiety and Depression in Hemodialysis Patients." Nobel Medicus, 6, 39–44, January 2011.
• S. Yarman et al. "Interleukin-6-producing Pheochromocytoma Presenting with Fever of Unknown Origin." Clinics, 66, 1843–1846, October 2011. DOI:10.1590/S1807-59322011001000028.
• O. Oğuz et al. "Is Automated Kinetic Measurement Superior to End-point for Advanced Oxidation Protein Product?" Clinical Laboratory, 60, November 2014. DOI:10.7754/Clin.Lab.2013.130727.
• S. Civelek et al. "Soluble Lectin-like Oxidized LDL Receptor 1 as a Possible Mediator of Endothelial Dysfunction in Patients with Metabolic Syndrome." Journal of Clinical Laboratory Analysis, July 2014.
• B.B. İnal et al. "Evaluation of MDRD, Cockcroft-Gault, CKD-EPI Formulas in the Estimated Glomerular Filtration Rate." Clinical Laboratory, October 2014.
• E. Altunoğlu et al. "Ischemia-modified Albumin and Advanced Oxidation Protein Products as Potential Biomarkers of Protein Oxidation in Alzheimer’s Disease." Geriatrics Gerontology International, 15:872–880, 2015. DOI:10.1111/ggi.12361.
• C. Alkac et al. "Osteoprotegerin as a Marker of Atherosclerosis in Type 1 and Type 2 Diabetic Patients." Turk J Med Sci 2015;45:1306–1311.
• P. Demir et al. "Serum Osteoprotegerin Levels Related with Cardiovascular Risk Factors in Chronic Kidney Disease." Journal of Clinical Laboratory Analysis, 2016;1:1–7.
• L. Tokgözoglu et al. "Turkish Assessment of SURF Study: Control Rates of Cardiovascular Risk Factors Derived from Databases of 15 Different Levels of Health Centers in Turkey." Turk Kardiyol Dern Ars, 2017;45(5):398–407.
• P. Atukeren et al. "The Efficacy of Donepezil Administration on Acetylcholinesterase Activity and Altered Redox Homeostasis in Alzheimer’s Disease." Biomedicine-Pharmacotherapy, 2017;90(4):786–795.
• O. Tabak et al. "The Relationship Between Circulating Irisin, Retinol Binding Protein-4, Adiponectin and Inflammatory Mediators in Patients with Metabolic Syndrome." Archives of Endocrinology and Metabolism, 2017;61(6):1–9.
• M.E.H. Şahin et al. "A Case of Hide and Seek: An Obstructive Duodenal Tumor Resembling Superior Mesenteric Artery Syndrome." Journal of Gastrointestinal Cancer Stromal Tumor, 2018. DOI:10.4172/2572-4126.1000120.
• F. Erdenen et al. "Association of Plasma Pentraxin-3 Levels with Retinopathy and Systemic Factors in Diabetic Patients." Metabolic Syndrome Related Disorders, July 2018. DOI:10.1089/met.2018.0023.
• D. Sak et al. "The Relationship Between Plasma Taurine Levels and Complications in Patients with Type 2 Diabetes Mellitus." Biomolecules, 2019;9,96. DOI:10.3390/biom9030096.
• M.A. Al-Hayali et al. "Clinical Value of Circulating Microribonucleic Acids miR-1 and miR-21 in Evaluating the Diagnosis of Acute Heart Failure in Asymptomatic Type 2 Diabetic Patients." Biomolecules, 2019;9,93. DOI:10.3390/biom9050193.
• N. Saitogullari et al. "Evaluation of Serum Zonulin Level in Prediabetic Patients." Annales d’Endocrinologie, 2020. DOI:10.1016/J.ando.2020.11.004.
• D. Koksalan et al. "Cardiovascular Disease in Type 2 Diabetes Mellitus: Relationship Between Microalbuminuria and Cardiovascular Risk Factors." Ann Med Res 2021;28:2097–2102. DOI:10.5455/annlsmedres.2021.03.233.
• E. Altunoğlu et al. "An Analysis of Circulating Betatrophin Levels in Relation with Type 1 and Type 2 Diabetes Mellitus." Annals of Endocrinology and Metabolism 2021;4:61–67. DOI:10.36959/433/568.